• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

Vaccine-In-A-Pill For Norovirus, The Infamous Winter Bug, Performs Well In Early Trials

March 14, 2025 by Deborah Bloomfield

A vaccine against norovirus, the dreaded “winter vomiting bug”, could be closer than you think: early clinical trials have returned positive results for a vaccine candidate that is taken orally as a pill. The trial targeted older adults, who are particularly at risk from severe complications from the infection that causes annual misery for so many.

ADVERTISEMENT

When we say “vaccine” we immediately think “injection”, but there is a precedent for oral vaccines – most notably the oral polio vaccine that millennials of a certain age almost certainly received as a small children. 

In this case, the pill, called VXA-G1.1-NN, has been designed to deliver a harmless viral vector carrying a norovirus protein directly to the small intestine. This is not the only norovirus vaccine currently in trials – for example, a trial of an mRNA vaccine was launched in the UK last year – but developers Vaxart believe there are a lot of advantages to their pill format.

Writing on their website, they explain that the platform is adaptable to both existing and emerging diseases, avoids problems with storage, eliminates the risk of needlestick injuries, and promotes strong immune responses at mucosal barrier surfaces.

This last point is particularly important with norovirus. It means that, in response to the vaccine, the body builds its defenses right at the places where the virus is likely to try and gain entry – the lining of the nose and mouth, for instance. 

“Given that norovirus is transmitted through mucosal routes, a vaccine that elicits protective immunity at barrier surfaces would be desirable,” write the study authors in their paper. 

Norovirus outbreaks are so hard to control because as few as 10 viral particles are enough to spark an infection. The virus is not easily killed by hand sanitizers, so regular soap and water and surface cleaners with bleach are the best tools we have to stop it. However, given that someone who’s been struck down with the disease can remain infectious for weeks after their symptoms have gone, it’s easy to see how the virus can spread like wildfire in settings like schools, care homes, and cruise ships. 

ADVERTISEMENT

Most people will recover from a bout of norovirus within a few very unpleasant days, but the consequences can be much more serious in older people. Severe vomiting and diarrhea bring a risk of dehydration, which can be deadly if not treated. 

Unfortunately, it’s precisely this group of people who are more difficult to target with vaccines. The immune system starts to wind down a bit as we age, thanks to a process called immunosenescence. Basically, it becomes harder to elicit a strong response from it with a vaccine.

Add to that the fact that norovirus is not just one virus, but rather a group of them, and you have a complex problem on your hands.

However, Vaxart’s candidate vaccine pill appears to be hitting the right notes. In the trial, 65 adults aged 55-80 were stratified into three cohorts – low, medium, and high dose – and a placebo group. They were further divided into younger (55-65) and older (66-80) age groups. 

ADVERTISEMENT

Each treatment group was given two pills, with the second 28 days after the first as a booster. The vaccine was found to be safe, with no serious adverse events occurring.

Better still, it was effective. The team found that the pills elicited a strong antibody response in blood, saliva, and nasal secretions. The mucosal immunity lasted for 210 days, showing it was not a short-term response. 

“The mucosal response induced by VXA-G1.1-NN has the potential to inhibit infection, viral shedding, and transmission,” the authors conclude. While additional, larger trials will now be needed, they believe it is a positive first step. So much so, Vaxart just announced they are launching a Phase 1 trial for a second-generation norovirus vaccine pill, to run concurrently. 

For anyone who was struck down during the worse-than-usual norovirus season that hit UK and US headlines recently, this will be music to their ears.

ADVERTISEMENT

The study is published in the journal Science Translational Medicine. 

Deborah Bloomfield
Deborah Bloomfield

Related posts:

  1. Chinese court rules against #MeToo plaintiff
  2. Deere workers reject six-year labor contract
  3. What Was The Egyptian Book Of The Dead?
  4. Mysterious Low Rumbling Noise Heard In Florida For Years Gets NSFW Explanation

Source Link: Vaccine-In-A-Pill For Norovirus, The Infamous Winter Bug, Performs Well In Early Trials

Filed Under: News

Primary Sidebar

  • First-Ever Recording Of Black Hole Recoil Captured During Merger – And You Can Listen To It
  • The Moon Is Moving Away From Earth At A Rate Of About 3.8 Centimeters Per Year. Will It Ever Drift Apart?
  • As Solar Storm Hits Earth NASA Finds “The Sun Is Slowly Waking Up”
  • Plate Tectonics And CO2 On Planets Suggest Alien Civilizations “Are Probably Pretty Rare”
  • How To Watch The “Awkward” Partial Solar Eclipse This Weekend
  • World’s Oldest Pots: 20,000-Year-Old Vessels May Have Been Used For Cooking Clams Or Brewing Beer
  • “The Body Is Slowly And Continuously Heated”: 14,000-Year-Old Smoked Mummies Are World’s Oldest
  • Pizza Slices, Polaroid Pictures, And Over 300 Hats: What’s Left Behind In Yellowstone’s Hydrothermal Areas?
  • The Mathematical Paradox That Lets You Create Something From Nothing
  • Ancient Asteroid Ripped Apart In Collision Had Flowing Water
  • Flying Foxes Include The World’s Biggest Bat And The Largest Mammal Capable Of True Flight
  • NASA Responds To Claims That Interstellar Object 3I/ATLAS Is An Advanced Alien Spacecraft
  • Millions Of Tons Of Gold Are In Earth’s Oceans, Potentially Worth Over $2 Quadrillion
  • The Race Back To The Moon: US Vs China, Will What Happens Next Change The Future?
  • NOAA Issues G3 Geomagnetic Storm Warning As 500,000 Kilometer Hole Sends Solar Wind At Earth
  • Lasting 776 Days, This Is The Longest Case Of COVID-19 Ever Recorded
  • Living Cement: The Microbes In Your Walls Could Power The Future
  • What Can Your Earwax Reveal About Your Health?
  • Ever Seen A Giraffe Use An Inhaler? Now You Can, And It’s Incredibly Wholesome
  • Martian Mudstone Has Features That Might Be Biosignatures, New Brain Implant Can Decode Your Internal Monologue, And Much More This Week
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version